- Home
- TNGX vs ATYR Comparison
TNGX vs ATYR Comparison
Compare TNGX & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- ATYR
- Stock Information
- Founded
- TNGX 2014
- ATYR 2005
- Country
- TNGX United States
- ATYR United States
- Employees
- TNGX N/A
- ATYR N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TNGX Health Care
- ATYR Health Care
- Exchange
- TNGX Nasdaq
- ATYR Nasdaq
- Market Cap
- TNGX 723.2M
- ATYR 535.0M
- IPO Year
- TNGX N/A
- ATYR 2015
- Fundamental
- Price
- TNGX $6.53
- ATYR $6.03
- Analyst Decision
- TNGX Strong Buy
- ATYR Strong Buy
- Analyst Count
- TNGX 6
- ATYR 5
- Target Price
- TNGX $10.00
- ATYR $23.25
- AVG Volume (30 Days)
- TNGX 1.4M
- ATYR 4.9M
- Earning Date
- TNGX 11-05-2025
- ATYR 11-06-2025
- Dividend Yield
- TNGX N/A
- ATYR N/A
- EPS Growth
- TNGX N/A
- ATYR N/A
- EPS
- TNGX N/A
- ATYR N/A
- Revenue
- TNGX $24,296,000.00
- ATYR N/A
- Revenue This Year
- TNGX $6.56
- ATYR $478.72
- Revenue Next Year
- TNGX N/A
- ATYR $1,899.26
- P/E Ratio
- TNGX N/A
- ATYR N/A
- Revenue Growth
- TNGX N/A
- ATYR N/A
- 52 Week Low
- TNGX $1.03
- ATYR $1.67
- 52 Week High
- TNGX $10.85
- ATYR $7.29
- Technical
- Relative Strength Index (RSI)
- TNGX 47.47
- ATYR 62.69
- Support Level
- TNGX $6.25
- ATYR $5.08
- Resistance Level
- TNGX $7.40
- ATYR $5.77
- Average True Range (ATR)
- TNGX 0.40
- ATYR 0.47
- MACD
- TNGX -0.06
- ATYR 0.04
- Stochastic Oscillator
- TNGX 24.35
- ATYR 68.03
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.